5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Lymphoma O
and O
Other O
Malignancies O
: O
Risk O
of O
lymphomas O
, O
including O
post O
transplant O
lymphoproliferative O
disorder O
( O
PLTD O
) O
; O
appears O
related O
to O
intensity O
and O
duration O
of O
use O
. O

Avoid O
prolonged O
exposure O
to O
UV O
light O
and O
sunlight O
( O
5.2 O
) O
* O
Serious O
infections O
: O
Increased O
risk O
of O
bacterial O
, O
viral O
, O
fungal O
and O
protozoal O
infections O
, O
including O
opportunistic O
infections O
: O
combination O
immunosuppression O
should O
be O
used O
with O
caution O
( O
5.3 O
) O
* O
Polyoma O
Virus O
Infections O
: O
Serious O
, O
sometimes O
fatal O
outcomes O
, O
including O
polyoma O
virus-associated O
nephropathy O
( O
PVAN O
) O
, O
mostly O
due O
to O
BK O
virus O
, O
and O
JC O
virus-associated O
progressive O
multifocal O
leukoencephalopathy O
( O
PML O
) O
; O
consider O
reducing O
immunosuppression O
( O
5.4 O
) O
* O
Cytomegalovirus O
( O
CMV O
) O
Infections O
: O
Increased O
risk O
of O
CMV O
viremia O
and O
disease O
; O
consider O
reducing O
immunosuppression O
( O
5.5 O
) O
* O
New O
Onset O
Diabetes O
After O
Transplant O
: O
Monitor O
blood O
glucose O
( O
5.6 O
) O
* O
Nephrotoxicity O
: O
Acute O
and/or O
chronic O
; O
reduce O
the O
dose O
; O
use O
caution O
with O
other O
nephrotoxic O
drugs O
( O
5.7 O
) O
* O
Neurotoxicity O
: O
Risk O
of O
Posterior O
Reversible O
Encephalopathy O
Syndrome O
, O
monitor O
for O
neurologic O
abnormalities O
; O
reduce O
or O
discontinue O
Prograf O
and O
other O
immunosuppressants O
( O
5.8 O
) O
* O
Hyperkalemia O
: O
Monitor O
serum O
potassium O
levels O
. O

Careful O
consideration O
should O
be O
given O
prior O
to O
use O
of O
other O
agents O
also O
associated O
with O
hyperkalemia O
( O
5.9 O
) O
* O
Hypertension O
: O
May O
require O
antihypertensive O
therapy O
. O

Monitor O
relevant O
drug-drug O
interactions O
( O
5.10 O
) O
* O
Anaphylactic O
Reactions O
with O
IV O
formulation O
: O
Observe O
patients O
receiving O
Prograf O
injection O
for O
signs O
and O
symptoms O
of O
anaphylaxis O
( O
5.11 O
) O
* O
Use O
with O
Sirolimus O
: O
Not O
recommended O
in O
liver O
and O
heart O
transplant O
due O
to O
increased O
risk O
of O
serious O
adverse O
reactions O
( O
5.12 O
) O
* O
Myocardial O
Hypertrophy O
: O
Consider O
dosage O
reduction O
or O
discontinuation O
( O
5.15 O
) O
* O
Immunizations O
: O
Use O
of O
live O
vaccines O
should O
be O
avoided O
( O
5.16 O
) O
* O
Pure O
Red O
Cell O
Aplasia O
: O
Discontinuation O
should O
be O
considered O
( O
5.17 O
) O
5.1 O
Management O
of O
Immunosuppression O
Only O
physicians O
experienced O
in O
immunosuppressive B-NonOSE_AE
therapy I-NonOSE_AE
and O
management O
of O
organ B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
should O
use O
Prograf O
. O

Patients O
receiving O
the O
drug O
should O
be O
managed O
in O
facilities O
equipped O
and O
staffed O
with O
adequate O
laboratory O
and O
supportive O
medical O
resources O
. O

The O
physicians O
responsible O
for O
maintenance O
therapy O
should O
have O
complete O
information O
requisite O
for O
the O
follow O
up O
of O
the O
patient O
[ O
see O
Boxed O
Warning O
] O
. O

5.2 O
Lymphoma O
and O
Other O
Malignancies O
Patients O
receiving O
immunosuppressants O
, O
including O
Prograf O
, O
are O
at O
increased O
risk O
of O
developing O
lymphomas B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
, O
particularly O
of O
the O
skin I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
] O
. O

The O
risk O
appears O
to O
be O
related O
to O
the O
intensity O
and O
duration O
of O
immunosuppression B-NonOSE_AE
rather O
than O
to O
the O
use O
of O
any O
specific O
agent O
. O

As O
usual O
for O
patients O
with O
increased O
risk O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
, O
exposure O
to O
sunlight O
and O
UV O
light O
should O
be O
limited O
by O
wearing O
protective O
clothing O
and O
using O
a O
sunscreen O
with O
a O
high O
protection O
factor O
. O

Post B-OSE_Labeled_AE
transplant I-OSE_Labeled_AE
lymphoproliferative I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PTLD I-OSE_Labeled_AE
) O
has O
been O
reported O
in O
immunosuppressed B-Not_AE_Candidate
organ B-Not_AE_Candidate
transplant I-Not_AE_Candidate
recipients O
. O

The O
majority O
of O
PTLD B-OSE_Labeled_AE
events O
appear O
related O
to O
Epstein B-OSE_Labeled_AE
Barr I-OSE_Labeled_AE
Virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
EBV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

The O
risk O
of O
PTLD B-NonOSE_AE
appears O
greatest O
in O
those O
individuals O
who O
are O
EBV B-Not_AE_Candidate
seronegative I-Not_AE_Candidate
, O
a O
population O
which O
includes O
many O
young O
children O
. O

5.3 O
Serious O
Infections O
Patients O
receiving O
immunosuppressants O
, O
including O
Prograf O
, O
are O
at O
increased O
risk O
of O
developing O
bacterial B-OSE_Labeled_AE
, O
viral O
, O
fungal O
, O
and O
protozoal O
infections I-OSE_Labeled_AE
, O
including O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.4 O
, O
5.5 O
) O
] O
. O

These O
infections B-OSE_Labeled_AE
may O
lead O
to O
serious O
, O
including O
fatal B-NonOSE_AE
, O
outcomes O
. O

Because O
of O
the O
danger O
of O
oversuppression B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
immune I-NonOSE_AE
system I-NonOSE_AE
which O
can O
increase O
susceptibility B-NonOSE_AE
to I-NonOSE_AE
infection I-NonOSE_AE
, O
combination O
immunosuppressant B-NonOSE_AE
therapy I-NonOSE_AE
should O
be O
used O
with O
caution O
. O

5.4 O
Polyoma O
Virus O
Infections O
Patients O
receiving O
immunosuppressants O
, O
including O
Prograf O
, O
are O
at O
increased O
risk O
for O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
polyoma B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Polyoma B-NonOSE_AE
virus I-NonOSE_AE
infections I-NonOSE_AE
in O
transplant B-Not_AE_Candidate
patients O
may O
have O
serious O
, O
and O
sometimes O
fatal B-NonOSE_AE
, O
outcomes O
. O

These O
include O
polyoma B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PVAN I-OSE_Labeled_AE
) O
, O
mostly O
due O
to O
BK B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
JC B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
progressive I-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
which O
have O
been O
observed O
in O
patients O
receiving O
tacrolimus O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

PVAN B-NonOSE_AE
is O
associated O
with O
serious O
outcomes O
, O
including O
deteriorating B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
and O
kidney B-NonOSE_AE
graft I-NonOSE_AE
loss I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Patient O
monitoring O
may O
help O
detect O
patients O
at O
risk O
for O
PVAN B-NonOSE_AE
. O

Cases O
of O
PML B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Prograf O
. O

PML B-NonOSE_AE
, O
which O
is O
sometimes O
fatal B-NonOSE_AE
, O
commonly O
presents O
with O
hemiparesis B-NonOSE_AE
, O
apathy B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
cognitive B-NonOSE_AE
deficiencies I-NonOSE_AE
and O
ataxia B-NonOSE_AE
. O

Risk O
factors O
for O
PML B-NonOSE_AE
include O
treatment O
with O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
and O
impairment B-Not_AE_Candidate
of I-Not_AE_Candidate
immune I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

In O
immunosuppressed B-Not_AE_Candidate
patients O
, O
physicians O
should O
consider O
PML B-NonOSE_AE
in O
the O
differential O
diagnosis O
in O
patients O
reporting O
neurological B-NonOSE_AE
symptoms I-NonOSE_AE
and O
consultation O
with O
a O
neurologist O
should O
be O
considered O
as O
clinically O
indicated O
. O

Reductions O
in O
immunosuppression B-NonOSE_AE
should O
be O
considered O
for O
patients O
who O
develop O
evidence O
of O
PVAN B-NonOSE_AE
or O
PML B-NonOSE_AE
. O

Physicians O
should O
also O
consider O
the O
risk O
that O
reduced O
immunosuppression B-NonOSE_AE
represents O
to O
the O
functioning O
allograft O
. O

5.5 O
Cytomegalovirus O
( O
CMV O
) O
Infections O
Patients O
receiving O
immunosuppressants O
, O
including O
Prograf O
, O
are O
at O
increased O
risk O
of O
developing O
CMV B-OSE_Labeled_AE
viremia I-OSE_Labeled_AE
and O
CMV B-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

The O
risk O
of O
CMV B-OSE_Labeled_AE
disease I-OSE_Labeled_AE
is O
highest O
among O
transplant B-Not_AE_Candidate
recipients O
seronegative B-Not_AE_Candidate
for I-Not_AE_Candidate
CMV I-Not_AE_Candidate
at O
time O
of O
transplant B-NonOSE_AE
who O
receive O
a O
graft O
from O
a O
CMV B-Not_AE_Candidate
seropositive I-Not_AE_Candidate
donor I-Not_AE_Candidate
. O

Therapeutic O
approaches O
to O
limiting O
CMV B-NonOSE_AE
disease I-NonOSE_AE
exist O
and O
should O
be O
routinely O
provided O
. O

Patient O
monitoring O
may O
help O
detect O
patients O
at O
risk O
for O
CMV B-NonOSE_AE
disease I-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
reducing O
the O
amount O
of O
immunosuppression B-NonOSE_AE
in O
patients O
who O
develop O
CMV B-NonOSE_AE
viremia I-NonOSE_AE
and/or O
CMV B-NonOSE_AE
disease I-NonOSE_AE
. O

5.6 O
New O
Onset O
Diabetes O
After O
Transplant O
Prograf O
was O
shown O
to O
cause O
new O
onset O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
in O
clinical O
trials O
of O
kidney B-Not_AE_Candidate
, O
liver O
, O
and O
heart O
transplantation I-Not_AE_Candidate
. O

New O
onset O
diabetes B-OSE_Labeled_AE
after O
transplantation B-Not_AE_Candidate
may O
be O
reversible O
in O
some O
patients O
. O

Black O
and O
Hispanic O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
are O
at O
an O
increased O
risk O
. O

Blood O
glucose O
concentrations O
should O
be O
monitored O
closely O
in O
patients O
using O
Prograf O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.7 O
Nephrotoxicity O
Prograf O
, O
like O
other O
calcineurin-inhibitors O
, O
can O
cause O
acute O
or O
chronic O
nephrotoxicity B-OSE_Labeled_AE
, O
particularly O
when O
used O
in O
high O
doses O
. O

Acute O
nephrotoxicity B-OSE_Labeled_AE
is O
most O
often O
related O
to O
vasoconstriction B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
afferent I-NonOSE_AE
renal I-NonOSE_AE
arteriole I-NonOSE_AE
, O
is O
characterized O
by O
increasing B-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
, O
hyperkalemia B-NonOSE_AE
, O
and/or O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
urine I-NonOSE_AE
output I-NonOSE_AE
, O
and O
is O
typically O
reversible O
. O

Chronic O
calcineurin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
inhibitor I-OSE_Labeled_AE
nephrotoxicity I-OSE_Labeled_AE
is O
associated O
with O
increased B-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
, O
decreased B-NonOSE_AE
kidney I-NonOSE_AE
graft I-NonOSE_AE
life I-NonOSE_AE
, O
and O
characteristic O
histologic O
changes B-NonOSE_AE
observed I-NonOSE_AE
on I-NonOSE_AE
renal I-NonOSE_AE
biopsy I-NonOSE_AE
; O
the O
changes O
associated O
with O
chronic O
calcineurin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
inhibitor I-OSE_Labeled_AE
nephrotoxicity I-OSE_Labeled_AE
are O
typically O
progressive O
. O

Patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
should O
be O
monitored O
closely O
as O
the O
dosage O
of O
Prograf O
may O
need O
to O
be O
reduced O
. O

In O
patients O
with O
persistent O
elevations B-Not_AE_Candidate
of I-Not_AE_Candidate
serum I-Not_AE_Candidate
creatinine I-Not_AE_Candidate
who O
are O
unresponsive O
to O
dosage O
adjustments O
, O
consideration O
should O
be O
given O
to O
changing O
to O
another O
immunosuppressive B-NonOSE_AE
therapy I-NonOSE_AE
. O

Based O
on O
reported O
adverse O
reactions O
terms O
related O
to O
decreased B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
nephrotoxicity B-OSE_Labeled_AE
was O
reported O
in O
approximately O
52 O
% O
of O
kidney B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
and O
in O
40 O
% O
and O
36 O
% O
of O
liver B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
receiving O
Prograf O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
, O
and O
in O
59 O
% O
of O
heart B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
in O
a O
European O
randomized O
trial O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Due O
to O
the O
potential O
for O
additive O
or O
synergistic O
impairment B-NonOSE_AE
of I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
, O
care O
should O
be O
taken O
when O
administering O
Prograf O
with O
drugs O
that O
may O
be O
associated O
with O
renal B-NonOSE_AE
dysfunction I-NonOSE_AE
. O

These O
include O
, O
but O
are O
not O
limited O
to O
, O
aminoglycosides O
, O
ganciclovir O
, O
amphotericin O
B O
, O
cisplatin O
, O
nucleotide O
reverse O
transcriptase O
inhibitors O
( O
e.g. O
, O
tenofovir O
) O
and O
protease O
inhibitors O
( O
e.g. O
, O
ritonavir O
, O
indinavir O
) O
. O

Similarly O
, O
care O
should O
be O
exercised O
when O
administering O
with O
CYP3A4 O
inhibitors O
such O
as O
antifungal O
drugs O
( O
e.g. O
, O
ketoconazole O
) O
, O
calcium O
channel O
blockers O
( O
e.g. O
, O
diltiazem O
, O
verapamil O
) O
, O
and O
macrolide O
antibiotics O
( O
e.g. O
, O
clarithromycin O
, O
erythromycin O
, O
troleandomycin O
) O
which O
will O
result O
in O
increased O
tacrolimus O
whole O
blood O
concentrations O
due O
to O
inhibition O
of O
tacrolimus O
metabolism O
[ O
see O
Drug O
Interactions O
( O
7.3 O
, O
7.4 O
, O
7.5 O
, O
7.6 O
) O
] O
. O

5.8 O
Neurotoxicity O
Prograf O
may O
cause O
a O
spectrum O
of O
neurotoxicities B-OSE_Labeled_AE
, O
particularly O
when O
used O
in O
high O
doses O
. O

The O
most O
severe O
neurotoxicities B-OSE_Labeled_AE
include O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
, O
delirium B-OSE_Labeled_AE
, O
and O
coma B-OSE_Labeled_AE
. O

Patients O
treated O
with O
tacrolimus O
have O
been O
reported O
to O
develop O
PRES B-OSE_Labeled_AE
. O

Symptoms O
indicating O
PRES B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
seizures B-NonOSE_AE
, O
visual B-NonOSE_AE
disturbances I-NonOSE_AE
and O
hypertension B-NonOSE_AE
. O

Diagnosis O
may O
be O
confirmed O
by O
radiological O
procedure O
. O

If O
PRES B-NonOSE_AE
is O
suspected O
or O
diagnosed O
, O
blood O
pressure O
control O
should O
be O
maintained O
and O
immediate O
reduction O
of O
immunosuppression B-NonOSE_AE
is O
advised O
. O

This O
syndrome O
is O
characterized O
by O
reversal O
of O
symptoms O
upon O
reduction O
or O
discontinuation O
of O
immunosuppression B-NonOSE_AE
. O

Coma B-OSE_Labeled_AE
and O
delirium B-OSE_Labeled_AE
, O
in O
the O
absence O
of O
PRES B-NonOSE_AE
, O
have O
also O
been O
associated O
with O
high O
plasma O
concentrations O
of O
tacrolimus O
. O

Seizures B-OSE_Labeled_AE
have O
occurred O
in O
adult O
and O
pediatric O
patients O
receiving O
Prograf O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Less O
severe O
neurotoxicities B-OSE_Labeled_AE
, O
include O
tremors B-OSE_Labeled_AE
, O
paresthesias B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
other O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
motor I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
mental O
status O
, O
and O
sensory O
function O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Tremor B-OSE_Labeled_AE
and O
headache B-OSE_Labeled_AE
have O
been O
associated O
with O
high O
whole-blood O
concentrations O
of O
tacrolimus O
and O
may O
respond O
to O
dosage O
adjustment O
. O

5.9 O
Hyperkalemia O
Hyperkalemia B-OSE_Labeled_AE
has O
been O
reported O
with O
Prograf O
use O
. O

Serum O
potassium O
levels O
should O
be O
monitored O
. O

Careful O
consideration O
should O
be O
given O
prior O
to O
use O
of O
other O
agents O
also O
associated O
with O
hyperkalemia B-NonOSE_AE
( O
e.g. O
, O
potassium-sparing O
diuretics O
, O
ACE O
inhibitors O
, O
angiotensin O
receptor O
blockers O
) O
during O
Prograf O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.10 O
Hypertension O
Hypertension B-OSE_Labeled_AE
is O
a O
common O
adverse O
effect O
of O
Prograf O
therapy O
and O
may O
require O
antihypertensive O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
control O
of O
blood O
pressure O
can O
be O
accomplished O
with O
any O
of O
the O
common O
antihypertensive O
agents O
, O
though O
careful O
consideration O
should O
be O
given O
prior O
to O
use O
of O
antihypertensive O
agents O
associated O
with O
hyperkalemia B-NonOSE_AE
( O
e.g. O
, O
potassium-sparing O
diuretics O
, O
ACE O
inhibitors O
, O
angiotensin O
receptor O
blockers O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
. O

Calcium-channel O
blocking O
agents O
may O
increase O
tacrolimus O
blood O
concentrations O
and O
therefore O
require O
dosage O
reduction O
of O
Prograf O
[ O
see O
Drug O
Interactions O
( O
7.5 O
) O
] O
. O

5.11 O
Anaphylactic O
Reactions O
with O
Prograf O
Injection O
Anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
occurred O
with O
injectables O
containing O
castor O
oil O
derivatives O
, O
including O
Prograf O
, O
in O
a O
small O
percentage O
of O
patients O
( O
0.6 O
% O
) O
. O

The O
exact O
cause O
of O
these O
reactions O
is O
not O
known O
. O

Prograf O
injection O
should O
be O
reserved O
for O
patients O
who O
are O
unable O
to O
take O
Prograf O
capsules O
[ O
see O
Indications O
and O
Usage O
( O
1.4 O
) O
] O
. O

Patients O
receiving O
Prograf O
injection O
should O
be O
under O
continuous O
observation O
for O
at O
least O
the O
first O
30 O
minutes O
following O
the O
start O
of O
the O
infusion O
and O
at O
frequent O
intervals O
thereafter O
. O

If O
signs O
or O
symptoms O
of O
anaphylaxis B-NonOSE_AE
occur O
, O
the O
infusion O
should O
be O
stopped O
. O

An O
aqueous O
solution O
of O
epinephrine O
should O
be O
available O
at O
the O
bedside O
as O
well O
as O
a O
source O
of O
oxygen O
. O

5.12 O
Use O
with O
Sirolimus O
The O
safety O
and O
efficacy O
of O
Prograf O
with O
sirolimus O
has O
not O
been O
established O
in O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
. O

Use O
of O
sirolimus O
with O
Prograf O
in O
studies O
of O
de O
novo O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
was O
associated O
with O
an O
excess O
mortality B-NonOSE_AE
, O
graft B-NonOSE_AE
loss I-NonOSE_AE
, O
and O
hepatic B-NonOSE_AE
artery I-NonOSE_AE
thrombosis I-NonOSE_AE
( I-NonOSE_AE
HAT I-NonOSE_AE
) O
and O
is O
not O
recommended O
[ O
see O
Indications O
and O
Usage O
( O
1.4 O
) O
] O
. O

Use O
of O
sirolimus O
( O
2 O
mg O
per O
day O
) O
with O
Prograf O
in O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
in O
a O
U.S O
. O
trial O
was O
associated O
with O
increased O
risk O
of O
renal B-NonOSE_AE
function I-NonOSE_AE
impairment I-NonOSE_AE
, O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
, O
and O
insulin B-NonOSE_AE
- I-NonOSE_AE
dependent I-NonOSE_AE
post I-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
diabetes I-NonOSE_AE
mellitus I-NonOSE_AE
, O
and O
is O
not O
recommended O
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
. O

5.13 O
Use O
with O
CYP3A4 O
Inhibitors O
and O
Inducers O
When O
coadministering O
Prograf O
with O
strong O
CYP3A4-inhibitors O
( O
e.g. O
, O
telaprevir O
, O
boceprevir O
, O
ritonavir O
, O
ketoconazole O
, O
itraconazole O
, O
voriconazole O
, O
clarithromycin O
) O
and O
strong O
inducers O
( O
e.g. O
, O
rifampin O
, O
rifabutin O
) O
adjustments O
in O
the O
dosing O
regimen O
of O
Prograf O
and O
subsequent O
frequent O
monitoring O
of O
tacrolimus O
whole O
blood O
trough O
concentrations O
and O
tacrolimus-associated O
adverse O
reactions O
are O
recommended O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.14 O
QT O
Prolongation O
Prograf O
may O
prolong B-OSE_Labeled_AE
the I-OSE_Labeled_AE
QT I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
and O
may O
cause O
Torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
Pointes I-OSE_Labeled_AE
. O

Avoid O
Prograf O
in O
patients O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
. O

In O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
bradyarrhythmias B-Not_AE_Candidate
, O
those O
taking O
certain O
antiarrhythmic O
medications O
or O
other O
medicinal O
products O
that O
lead O
to O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
, O
and O
those O
with O
electrolyte B-Not_AE_Candidate
disturbances I-Not_AE_Candidate
such O
as O
hypokalemia B-Not_AE_Candidate
, O
hypocalcemia B-Not_AE_Candidate
, O
or O
hypomagnesemia B-Not_AE_Candidate
, O
consider O
obtaining O
electrocardiograms O
and O
monitoring O
electrolytes O
( O
magnesium O
, O
potassium O
, O
calcium O
) O
periodically O
during O
treatment O
. O

When O
coadministering O
Prograf O
with O
other O
substrates O
and/or O
inhibitors O
of O
CYP3A4 O
that O
also O
have O
the O
potential O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QT I-NonOSE_AE
interval I-NonOSE_AE
, O
a O
reduction O
in O
Prograf O
dose O
, O
frequent O
monitoring O
of O
tacrolimus O
whole O
blood O
concentrations O
, O
and O
monitoring O
for O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
is O
recommended O
. O

Use O
of O
Prograf O
with O
amiodarone O
has O
been O
reported O
to O
result O
in O
increased O
tacrolimus O
whole O
blood O
concentrations O
with O
or O
without O
concurrent O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.15 O
Myocardial O
Hypertrophy O
Myocardial B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
has O
been O
reported O
in O
infants O
, O
children O
, O
and O
adults O
, O
particularly O
those O
with O
high O
tacrolimus O
trough O
concentrations O
, O
and O
is O
generally O
manifested O
by O
echocardiographically O
demonstrated O
concentric O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
posterior I-OSE_Labeled_AE
wall I-OSE_Labeled_AE
and O
interventricular O
septum O
thickness I-OSE_Labeled_AE
. O

This O
condition O
appears O
reversible O
in O
most O
cases O
following O
dose O
reduction O
or O
discontinuance O
of O
therapy O
. O

In O
patients O
who O
develop O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
or O
clinical O
manifestations O
of O
ventricular B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
while O
receiving O
Prograf O
therapy O
, O
echocardiographic O
evaluation O
should O
be O
considered O
. O

If O
myocardial B-NonOSE_AE
hypertrophy I-NonOSE_AE
is O
diagnosed O
, O
dosage O
reduction O
or O
discontinuation O
of O
Prograf O
should O
be O
considered O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.16 O
Immunizations O
The O
use O
of O
live O
vaccines O
should O
be O
avoided O
during O
treatment O
with O
tacrolimus O
; O
examples O
include O
( O
not O
limited O
to O
) O
the O
following O
: O
intranasal O
influenza O
, O
measles O
, O
mumps O
, O
rubella O
, O
oral O
polio O
, O
BCG O
, O
yellow O
fever O
, O
varicella O
, O
and O
TY21a O
typhoid O
vaccines O
. O

5.17 O
Pure O
Red O
Cell O
Aplasia O
Cases O
of O
pure B-OSE_Labeled_AE
red I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
aplasia I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRCA I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
treated O
with O
tacrolimus O
. O

A O
mechanism O
for O
tacrolimus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
PRCA I-OSE_Labeled_AE
has O
not O
been O
elucidated O
. O

All O
patients O
reported O
risk O
factors O
for O
PRCA B-NonOSE_AE
such O
as O
parvovirus B-Not_AE_Candidate
B I-Not_AE_Candidate
1 I-Not_AE_Candidate
9 I-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
underlying O
disease O
, O
or O
concomitant O
medications O
associated O
with O
PRCA B-NonOSE_AE
. O

If O
PRCA B-NonOSE_AE
is O
diagnosed O
, O
discontinuation O
of O
Prograf O
should O
be O
considered O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.18 O
Gastrointestinal O
Perforation O
Gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
treated O
with O
Prograf O
; O
all O
reported O
cases O
were O
considered O
to O
be O
a O
complication O
of O
transplant B-Not_AE_Candidate
surgery O
or O
accompanied O
by O
infection B-Not_AE_Candidate
, O
diverticulum B-Not_AE_Candidate
, O
or O
malignant B-Not_AE_Candidate
neoplasm I-Not_AE_Candidate
. O

As O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
may O
be O
serious O
or O
life-threatening O
, O
appropriate O
medical/surgical O
management O
should O
be O
instituted O
promptly O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

